US Healthcare Costs Skyrocket as Startups Push Alternatives

The US healthcare system’s cost-outcome paradox remains unsolved

A 2023 study published by a major medical journal found the US spends more on healthcare than any nation in the G7 while delivering worse outcomes for preventable conditions like diabetes and heart disease. This contradiction has birthed a new wave of startups targeting specific fractures in the system—not with broad overhauls, but by rethinking how care and insurance are delivered to niche populations.

Two models stand out for their direct approaches to cost and complexity. Evry Health, a 2018 Y Combinator graduate, offers employer-based insurance without copays or deductibles to companies with 51+ employees in Texas. Meanwhile, Meto—a digital metabolic health platform—uses AI and continuous monitoring to treat conditions like insulin resistance and hormonal imbalances, billing itself as “Medical First, Not Tech.” Both companies reject the industry’s standard playbook of opaque pricing and fragmented care.

Startups tackle different pain points

Evry’s model hinges on simplicity. Employers pay a fixed monthly premium per employee, with no additional costs for mental health visits or virtual consultations. The plan’s zero-copay structure for primary care and specialists contrasts sharply with the $150-$300 out-of-pocket costs common in traditional plans. By limiting eligibility to Texas-based employers (and later expanding regionally), Evry argues it can negotiate better rates with local providers while avoiding the administrative bloat of national insurance networks.

Meto takes a different angle: instead of insuring against costs, it targets the root causes of chronic conditions driving them. Users pay $0-$50 per session for AI-assisted diagnostic panels and provider-led care plans, with a focus on lab-driven insights rather than generic wellness advice. The platform’s emphasis on continuous monitoring—tracking biometrics and adjusting treatment over time—reflects a shift toward personalized, preventive care. Early users describe it as “diabetes care for people who don’t have a diabetes diagnosis yet,” addressing conditions like PCOS and thyroid imbalances before they escalate.

Why traditional models fail these startups

The US healthcare system’s core dysfunction—prices that don’t correlate with quality—creates both barriers and opportunities. For Evry, the hurdle is convincing employers to abandon established insurers offering broader geographic coverage. But Texas’s high health insurance premiums (22% above the national average) give the startup leverage. A 2022 report by the Commonwealth Fund found Texas employers with 100 employees paid an average of $16,400 per worker in health benefits, making Evry’s $4,200/month plan a tempting alternative for mid-sized companies.

Meto avoids the insurance market entirely, sidestepping the regulatory and pricing chaos that plagues competitors. By operating as a direct-to-consumer diagnostic and treatment service, it charges transparent rates for specific interventions rather than guaranteeing coverage for all possible expenses. This model works best for conditions like metabolic syndrome, where early intervention can reduce long-term costs. However, scaling requires partnerships with traditional insurers—something Meto claims to have secured with “most major providers,” though it declined to name them.

What to watch in 2024

Three developments will determine if these startups can disrupt their markets:

1. Evry’s expansion timeline: The company’s Texas-only restriction is both a strategic and legal limitation. If it secures multi-state licensure in 2024, it could pressure regional insurers to simplify their own offerings.
2. Meto’s clinical validation: The company’s success depends on proving that its AI-guided, lab-centric model improves patient outcomes. A peer-reviewed study showing measurable improvements in A1c levels or hormone balance would be a major milestone.
3. Regulatory pushback: Both companies operate in gray areas—Evry as an employer-based alternative insurer, Meto as a digital care platform. State-level Medicaid expansion efforts and the 2024 federal election could create new opportunities or obstacles.

The broader lesson is that neither cost nor quality can be solved in isolation. As one Meto user put it: “I wasn’t missing a pill—I was missing a system that actually listened.” For startups, the path forward lies in building those systems, not just selling access to them.

Updates

• 2026-08-05 — Klaviyo acquires Elias Torres’ Agency in full-circle reunion for tech founders (source)
• 2026-07-26 — 3 Clever Things You Can Do With an Old Amazon Kindle (source)